Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxidized and regenerated cellulose is a plant-derived bioabsorbable hemostatic agent used in surgical procedures to control capillary, venous, and small arterial bleeding when conventional methods (such as ligation or cautery) are impractical or ineffective. It is produced by the partial oxidation of regenerated cellulose fibers. Upon application to a bleeding site during surgery, it forms a gelatinous mass that acts as a physical matrix for platelet adhesion and clot formation. The low pH of the material also promotes vasoconstriction and inhibits bacterial growth. The product is fully absorbable within several weeks post-implantation with minimal tissue reaction. It does not induce an immune response and can be left in situ after surgery[2][3][4][5][6]. Its primary mechanism of action is physical—providing a scaffold for clot formation—and chemical—lowering local pH to promote hemostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxidized and regenerated cellulose.